Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions-Reference-Cited by-同舟云学术

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

Published:1999-12-01 Issue:11 Volume:104 Page:1527-1537
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Trepicchio William L.,Ozawa Maki,Walters Ian B.,Kikuchi Toyoko,Gilleaudeau Patricia,Bliss Judith L.,Schwertschlag Ullrich,Dorner Andrew J.,Krueger James G.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference52 articles.

1. Treatment of Psoriasis

2. Studies of the Effect of Cyclosporine in Psoriasis In Vivo: Combined Effects on Activated T Lymphocytes and Epidermal Regenerative Maturation

3. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

4. Treatment of Recalcitrant Plaque Psoriasis with a Humanized Non-depleting Antibody to CD4

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacologic inhibition of Il6st/gp130 improves dermatological inflammation and pruritus;Biomedicine & Pharmacotherapy;2024-09

2. Cytokines in psoriasis: From pathogenesis to targeted therapy;Human Immunology;2024-07

3. The Immunology of Psoriasis—Current Concepts in Pathogenesis;Clinical Reviews in Allergy & Immunology;2024-04-20

4. Interleukins and Psoriasis;Journal of Cutaneous Medicine and Surgery;2024-02-05

5. Advancements in non‐invasive skin sampling: Clinical conditions characterization via the assessment of skin surface cytokine biomarkers;Experimental Dermatology;2024-02